Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in
the US and remains the second leading cause of cancer deaths among
American men, with an estimated 174,000 new cases diagnosed in 2020.
Prostate cancer deaths are typically the result of
castration-resistant prostate cancer (CRPC), and most patients will
eventually experience disease progression despite castration, with a
median duration of response of 12–24 months. Fortunately for these
patients, novel therapies have changed the treatment paradigm, as
recent data has shown that newer options, including PARP inhibitors,
greatly improves outcomes. outcomes.
Upon completion of this
activity, participants will be able to:
-
Examine challenges to patient
adherence, administration and quality of life in the management
of prostate cancer
-
Discuss strategies to implement PARP
inhibitors into the treatment paradigm, especially as it relates
to patient adherence and quality of life
-
Define strategies for anticipating,
recognizing, and managing adverse events of PARP inhibitor
therapy in patients with prostate cancer
-
Explore the role of PARP inhibitors
in the management of prostate cancer
|
Faculty: |
Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed
Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC) |
|
Disclosure:
|
Dr. Agarwal
has served as a consultant for Astellas, AstraZeneca,
Argos, BMS, Bayer, Clovis, Eisai, Exelixis, EMD Serono,
Ely Lilly, Genentech, Merck, Medivation, Novartis,
Nektar, Pfizer, Pharmacyclics, and Seattle Genetics. He
has received grants/research funding from Active
Biotech, Astra Zeneca, Bavarian Nordic, Bayer Oncology,
BMS, Calithera, Celldex, Eisai, Exelixis, Genetech, GSK
(glaxosmithkline), Immunomedics, Janssen, Medivation,
Merck, New link Genetics, Novartis, Pfizer, Prometheus,
Rexahn, Sanofi, Takeda, and Tracon. His presentation has
been peer reviewed for any bias.
|
|
|
Planning Committee:
Bill Williams,
MD has no real or perceived financial relationships to
disclose.
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |